Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUPI REDUCE trial
NL-OMON60404Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dupilumab in atopic dermatitis (AD) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Mean Eczema Area and Severity Index at week 16. Started Aug 2023; status: active, not recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON60404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60404.